Dr. Patel is passionate about caring for patients with all forms of blood cancers and has a particular interest in lymphomas. He recognizes each patient's illness experience is unique and is focused on providing care that is both evidence-based and personalized to the individual patient. He values the importance of communication in the physician-patient experience and emphasizes shared decision making to help patients navigate their illness. He is excited to help develop novel therapies for blood cancer patients through clinical trials at Swedish. Dr. Patel enjoys traveling, cooking, and being outdoors with his wife. He is a keen sports fan and enjoys photographing the scenic PNW.Read More
Patel K, Abernethy A, Todd HK, Thomas Jr CR. Rapid Learning Systems. Oncologic Emergency Medicine: Principles and Practice. Springer International Publishing. p79-93. May 2016.
Patel K, Kim HS, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, van der Meer R, Nguyen P, Savage J, Owens KM, Vassilopoulos A, Ozden O, Park SH, Singh KK, Abdulkadir SA, Spitz DR, Deng CX, Gius D. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell. 2010; 17 (1): 41-52. PMID: 20129246.
Nguyen P, Cui H, Bisht KS, Sun L, Patel K, Lee RS, Kugoh H, Oshimura M, Feinberg AP, Gius D. CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region. Cancer Res. 2008; 68 (14): 5546-51. PMID: 18632606.
Patel K. "SIRT3 at the Junction of Superoxide Regulation." Platform Presentation. American Society for Therapeutic Radiology and Oncology (ASTRO) 50th Annual Meeting, Boston, Mass. Sept 21st-25th, 2008.
Patel K. "SIRT3 as a regulator of Intracellular Superoxide Levels." Platform Presentation. Mitochondrial Symposium National Institutes of Health. Bethesda, Md. January 11, 2008.